| 16.55 -3.66 (-18.11%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.74 |
1-year : | 25.21 |
| Resists | First : | 19.47 |
Second : | 21.59 |
| Pivot price | 19.79 |
|||
| Supports | First : | 16.05 |
Second : | 13.35 |
| MAs | MA(5) : | 19.12 |
MA(20) : | 20.06 |
| MA(100) : | 17.41  |
MA(250) : | 21.46 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 23.8 |
D(3) : | 22.8 |
| RSI | RSI(14): 29.3 |
|||
| 52-week | High : | 31.04 | Low : | 13.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FLGT ] has closed below the lower bollinger band by 34.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ FLGT ] is to continue within current trading range. Bollinger Bands are 6.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.52 - 17.61 | 17.61 - 17.68 |
| Low: | 15.85 - 15.94 | 15.94 - 16.01 |
| Close: | 16.41 - 16.56 | 16.56 - 16.67 |
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
Sat, 01 Aug 2026
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Fri, 31 Jul 2026
Fulgent Genetics (FLGT) Stock Price Slides As Losses Deepen Guidance Falls - simplywall.st
Fri, 31 Jul 2026
Fulgent Genetics Inc (FLGT) (Q2 2026) Earnings Call Highlights: Strategic Progress Amid Revenue Headwinds - GuruFocus
Thu, 30 Jul 2026
Fulgent Genetics Q2 Earnings Call Highlights - TradingView
Thu, 30 Jul 2026
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 30 Jul 2026
Fulgent Genetics (FLGT) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 28 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 36.6 (%) |
| Held by Institutions | 63.4 (%) |
| Shares Short | 2,750 (K) |
| Shares Short P.Month | 2,730 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 36.38 |
| Profit Margin | -23.1 % |
| Operating Margin | -45.1 % |
| Return on Assets (ttm) | -5.4 % |
| Return on Equity (ttm) | -7 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 4.36 |
| Sales Per Share | 11.27 |
| EBITDA (p.s.) | -2.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -90 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -6.9 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 1.46 |
| Price to Cash Flow | -5.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|